# ImmunoLogik GmbH jobs and careers

> 0 open roles at ImmunoLogik GmbH as of October 23, 2026. Source: https://www.thejobsmap.com/company/immunologik-gmbh

OUR SOLUTION APPROACH AGAINST SARS-CoV-2 IML-206 as a broad-spectrum antiviral drug for the treatment of patients infected with SARS-CoV-2 or other (future) coronaviruses. Unlike many other developments, the innovative substance IML-206 blocks specific cellular structures in humans, which are very likely indispensable for the replication of a broad range of coronavirus variants. OUR SOLUTION APPROACH AGAINST HIV RESISTANCES IML-106 for the efficient and essential treatment of patients who have exploited all available means of the modern therapy, and who would die due to the unavoidable outbreak of AIDS. The lead candidate targets directly the components of the host cell, which are essential for the replication of HIV. The goal is to significantly reduce the risk of resistant virus variations.

## Key facts

| | |
|---|---|
| Open roles | 0 |
| Headquarters | Berlin, Germany |
| Founded | 2012 |
| Employees | 1 to 10 |
| Total funding | $301K |
| Industries | Biotechnology |
| Website | https://immunologik.de |

## Leadership

- Christian Setz, CEO

## Common questions

### Is ImmunoLogik GmbH hiring right now?

ImmunoLogik GmbH has no open roles listed as of October 23, 2026. Roles appear here as soon as they are posted on ImmunoLogik GmbH's careers site.

### Where is ImmunoLogik GmbH headquartered?

ImmunoLogik GmbH is headquartered in Berlin, Germany and was founded in 2012.

### Who leads ImmunoLogik GmbH?

Christian Setz, CEO, is at the top of ImmunoLogik GmbH's org chart.

### How do I apply for a job at ImmunoLogik GmbH?

Pick a role on ImmunoLogik GmbH's TheJobsMap page and select Apply. Every listing links to the original posting on ImmunoLogik GmbH's own careers site, so you apply directly with the employer.